Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1594

Sort by

Sort Order Select

Journal Articles

Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.

Blood (2021) 137 (13): 1844.

https://doi.org/10.1182/blood.2021011330

Published: 2021

Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Blood (2021) 137 (5): 600–609.

https://doi.org/10.1182/blood.2020006578

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Amy S. Ruppert, Jesse G. Dixon, Gilles Salles, Anna Wall, David Cunningham, Viola Poeschel, Corinne Haioun, Herve Tilly, Herve Ghesquieres, Marita Ziepert, Jocelyne Flament, Christopher Flowers, Qian Shi, Norbert Schmitz

Blood (2020) 135 (23): 2041–2048.

https://doi.org/10.1182/blood.2019002729

Published: 2020

Includes: Supplemental data

Journal Articles

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

Stuart E. Lacy, Sharon L. Barrans, Philip A. Beer, Daniel Painter, Alexandra G. Smith, Eve Roman, Susanna L. Cooke, Camilo Ruiz, Paul Glover, Suzan J. L. Van Hoppe, Nichola Webster, Peter J. Campbell, Reuben M. Tooze, Russell Patmore, Cathy Burton, Simon Crouch, Daniel J. Hodson

Blood (2020) 135 (20): 1759–1771.

https://doi.org/10.1182/blood.2019003535

Published: 2020

Includes: Supplemental data

Journal Articles

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Blood (2020) 135 (16): 1396–1405.

https://doi.org/10.1182/blood.2019003526

Published: 2020

Includes: Supplemental data

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule

Blood (2019) 134 (Supplement_1): 3989.

https://doi.org/10.1182/blood-2019-129829

Published: 2019

Journal Articles

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Julie Devin, PharmD, Tatiana Cañeque, Yea-Lih Lin, PhD, Guillaume Cartron, Philippe Pasero, PhD, Caroline Bret, PhD PharmD, Raphael Rodriguez, Jerome Moreaux, PhD

Blood (2019) 134 (Supplement_1): 3960.

https://doi.org/10.1182/blood-2019-129954

Published: 2019

Journal Articles

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Blood (2019) 134 (Supplement_1): 3993.

https://doi.org/10.1182/blood-2019-125947

Published: 2019

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

Aleš Obr, MD PhD, Pavel Klener, Jr., Eva Kriegova, Dr, assoc prof, Zuzana Zemanova, PhD, Helena Urbankova, MSc, PhD, Andrea Jirkuvova, MD, Anna Petrackova, MSc, Barbora Cudova, Lenka Sedlarikova, MSc, VIT K Prochazka, MD, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3995.

https://doi.org/10.1182/blood-2019-123812

Published: 2019

Journal Articles

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Susanne Bram Ednersson, MD, Mimmie Stern, MD, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, MD PhD, Herman Nilsson-Ehle, MD PhD, Sverker Hasselblom, Per-Ola Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3967.

https://doi.org/10.1182/blood-2019-126387

Published: 2019

Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2019) 134 (Supplement_1): 3990.

https://doi.org/10.1182/blood-2019-126920

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Eliza A Hawkes, Hui-Peng Lee, MBChB, FRACP, FRCPA, BHB, Tara Cochrane, MBBS,FRCPA,FRACP, Chan Y. Cheah, Duncan Purtill, MBBS,FRCPA,FRACP, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, Christina Brown, PhDFRACP,FRCPA,MBBS, Nicholas E. Murphy, FRCPA,MBBS,FRACP, Jennifer Curnow, MBBS, FRACP, FRCPA, PhD, Julia Carlson, Belinda Butcher, BSci, MBiostat, PhD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4094.

https://doi.org/10.1182/blood-2019-124621

Published: 2019

Journal Articles

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Dimitrios Mougiakakos, MD, Simon Voelkl, PhD, Christian Bach, Andrej Stoll, Katrin Bitterer, Fabian Beier, MD, Jan Endell, Rainer Boxhammer, Jörg Thomas Bittenbring, MD, Andreas Mackensen, MD, Heiko Bruns, PhD

Blood (2019) 134 (Supplement_1): 4064.

https://doi.org/10.1182/blood-2019-124886

Published: 2019

Journal Articles

Real Life CNS-IPI Score Validation: A Retrospective Analysis of Two Centers in Brazil Outside of Clinical Trial

Thais Fischer, MD, Natalia Pin Chuen Zing, MD, Sérgio Costa Fortier, MD, Talita Silveira, Carlos Sérgio Chiattone, MD

Blood (2019) 134 (Supplement_1): 4133.

https://doi.org/10.1182/blood-2019-125576

Published: 2019

Journal Articles

Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome

Anna Dodero, MD, Anna Guidetti, MD, Fabrizio Marino, MD, Cristiana Carniti, PhD, Stefania Banfi, Alessandra Tucci, MD, Monica Balzarotti, Antonello Domenico Cabras, MD, Valentina Monti, PhD, Liliana Franca Devizzi, MD, Lucia Farina, MD, Maria Chiara Di Chio, MD, Giuseppe Rossi, Carmelo Carlo-Stella, MD, Paolo Corradini

Blood (2019) 134 (Supplement_1): 4116.

https://doi.org/10.1182/blood-2019-124350

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment of patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

The different flavors and splices of MCL

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Real Life CNS-IPI Score Validation: A Retrospective Analysis of Two Centers in Brazil Outside of Clinical Trial

Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only